API this morning confirmed that it will not participate in the current $600m Pharmacy Alliance tender process, with the company issuing a statement further detailing its dispute with the buying group. Despite yesterday saying it was inappropriate to comment on the matter, API has now provided further information about the disagreement, saying that as recently as last Dec it had reached agreement with Pharmacy Alliance (PAL) on an ongoing deal for API to be the group?s preferred wholesaler. API has taken exception to the issuing of the PAL tender, saying this ?effectively amounted to a unilateral repudiation of the agreement with API. ?In API?s view, this repudiation was not justified and is in breach of the agreement,? the company said, confirming that it?s ?considering its legal options? as a consequence. API ceo Stephen Roche said it was ?regrettable pharmacists had been caught up in a commercial dispute initiated by PAL,? assuring them that API has a ?highly competitive proposition and is confident of a satisfactory commercial outcome for API and its customers?.
API Price at posting:
27.5¢ Sentiment: Hold Disclosure: Held